The investment proceeds will be used both for Bluewater Bio’s current and forecast working capital needs and includes an exclusive right for Liberation Capital to invest in future water related infrastructure projects brought by Bluewater Bio.
Liberation Capital is a global private equity fund specialising in project finance for renewable energy and water/wastewater solutions. Liberation Capital focuses on small infrastructure projects with a preference for technologies and solutions that turn waste products into constituents of value.
Bluewater Bio is a global specialist in the treatment of wastewater. Its flagship technology, Hybacs, is a high performance cost-effective nutrient removal solution for municipal and industrial wastewater treatment, and in recent months Bluewater Bio has added to its technology portfolio through the acquisition of FilterClear filters, a range of high performance multimedia filters, and Water Innovate, the Cranfield University spin-out, including products such as N-Tox and MCR.
Jeff Garwood, managing member of Liberation Capital, said: “We have tremendous respect for Bluewater Bio’s strategy, technology and team. Daniel and I share a similar vision and as such we’re proud to be part of funding their growth. This was a complex transaction to be sure and will serve as a template for future funding as Bluewater grows its global footprint. This is a great deal for both partners.”
Source: Bluewater Bio
© FoodBev Media Ltd 2024